Medical and Health Congress

Posts Tagged ‘prostate cancer’

The Food and Drug Administration (FDA by its initials in English) on Thursday approved the first drug for prostate cancer chemotherapy to extend the survival of men who can no longer be helped by other treatments.

The drug is called Jevtana and is produced by French drugmaker Sanofi-Aventis. The FDA approved to treat Jevtana prostate cancer unresponsive to hormonal treatment or Docetaxel inhibition, the drug most commonly used to fight prostate tumors. Earlier this year, a study showed that lasted 10 weeks Jevtana survival of these patients.

Jevtana was approved for use in combination with the steroid prednisone, which is often used in cancer treatment.

In that study, patients received a treatment regimen that included Jevtana lived about a year and three months after starting treatment. Those who received the standard treatment lived for about a year and three weeks. There is hope that the drug will have a stronger effect in patients who are not so sick.
“Patients have few treatment options at this stage of the disease,” said Richard Pazdur, director of the Office of Oncology Products at the FDA. Sanofi-Aventis said it expects the drug will be available this summer.

The injection Jevtana applies. In the study, patients were more likely Jevtana their fears to shrink, those who received standard chemotherapy. However, no patients in the study had a complete remission or disappearance of all signs of the disease.

The FDA said side effects include decreased Jevtana levels of infection-fighting white blood cells, anemia, low platelets, diarrhea, fatigue, nausea, vomiting, constipation, weakness and kidney failure.

The FDA has approved this year two treatments for prostate cancer potentially revolutionary. In April approved the vaccine Provenge Dendreon Corp. The agency said prostate cancer is the second most common cancer in men in the United States. The disease usually occurs in older men.

The determination of Jevtana occurred more than three months before the FDA and schedules your decision making on the drug for 30 September. The drug was developed under the name of cabazitaxel. Jevtana is also being reviewed by regulators in other markets, including the European Union.

Prostate cancer is one of the greatest scourges of the male sector of the population. It is also one of the most common diseases within that social branch, and early diagnosis can save many lives. There is a massive aversion to the conduct of tests for the detection of this cancer, but is very necessary to be carried out in order to treat properly in the event of his appearance.

After 40 years of age is almost obligatory to do prostate exam every year. The most common is the digital rectal examination performed by a urologist, although there are several studies and analysis that can be used for the detection of cancer. Older people are more prone to this disease, which is very important to make an annual inspection to avoid any kind of surprise.

The list of symptoms of this disease is quite varied. If you experience any of these, you better do a check with your doctor you trust: painful urination, loss, blood in excreta and muscular pain in the spine area, groin and testicles. Remember that early diagnosis can help an effective treatment that reduces the risk of death.

Nor is it a matter of living scared, but it is always useful to encourage prevention. Note that maintaining good eating habits and physical activity significantly decreases the risk of prostate cancer. Also, remember that familial predisposition is also a condition to have this condition.

Genetic analysis predicts susceptibility to heart attacks and cancer The investigation was conducted by a university professor of 40 years that sequenced his own genome and discovered how the future was a high risk of dying from a heart attack and prostate cancer.
The analysis of a person’s genes can help predict the propensity to die from cancer or suffer a heart attack, released the magazine “The Lancet” in its latest issue.

During the study of their genes by experts from Stanford University found that the man has variants in three genes associated with sudden cardiac death, the TMEM43, DSP and MYBPC3.

The volunteer has a family history of sudden death, as a distant cousin died at age 19 of a heart attack while sleeping.

Genetic testing done from a computer algorithm showed that treatment with statins, a medicine used to lower cholesterol, boost your health. Read the rest of this entry »